COLIBRI-GI_Randomized phase 2 study of second-line chemotherapy comparing FOLFIRI + ivonescimab versus FOLFIRI + bevacizumab in Microsatellite Stable (MSS)/ proficient MisMatch Repair (pMMR) BRAF wild type (wt) advanced colorectal cancer (mCRC) without liver metastases

Patients with non resectable pMMR/MSS BRAF wt mCRC, without liver metastasis in the secondline setting after first-line FOLFOX-based chemotherapy

PFS is defined as the time from the date of randomization to the date of first documentation of disease progression as assessed by the investigator according to RECIST1.1, or death from any cause, or date of last follow-up for alive non progressive patients.

PFS as per iRECIST is defined as the time from the date of randomization to the date of first documentation of disease progression as assessed by the investigator according to iRECIST, or death from any cause, or date of last follow-up for alive non progressive patients., ORR is defined as the proportion of patients achieving complete response (CR) or partial response (PR) as assessed by the investigator according to RECIST v1.1., DOR is defined as the time from first documented PR or CR (compared to baseline measurement taken at screening) until the date of PD, as assessed by the investigator according to RECIST v1.1, or death from any cause., OS is defined as the time from randomization to death from any cause. Patients who are alive at the data-cutoff date will be censored on the last known alive date., Toxicity / Adverse events (AEs), occurrence of treatment-related AEs, treatment-related AEs (TRAEs) leading to dose reduction or discontinuation during treatment, serious adverse events (SAEs) and suspected unexpected serious adverse reactions (SUSARs), immune-related AEs (irAEs) graded according to NCI-CTCAE V6.0, QoL is assessed using the European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaires QLQ-C30 and EORTC QLQ-CR29

No related papers found yet.